Abstract Heart failure (HF) is characterized by molecular and cellular defects which jointly contribute to decreased cardiac pump function. During the development of the initial cardiac damage which leads to HF, adaptive responses activate physiological countermeasures to overcome depressed cardiac function and to maintain blood supply to vital organs in demand of nutrients. However, during the chronic course of most HF syndromes, these compensatory mechanisms are sustained beyond months and contribute to progressive maladaptive remodeling of the heart which is associated with a worse outcome. Of pathophysiological significance are mechanisms which directly control cardiac contractile function including ionand receptor-mediated intracellular signaling pathways. Importantly, signaling cascades of stress adaptation such as intracellular calcium (Ca 2? ) and 3 0 -5 0 -cyclic adenosine monophosphate (cAMP) become dysregulated in HF directly contributing to adverse cardiac remodeling and depression of systolic and diastolic function. Here, we provide an update about Ca 2? and cAMP dependent signaling changes in HF, how these changes affect cardiac function, and novel therapeutic strategies which directly address the signaling defects.
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Introduction
Congestive heart failure (HF) is a condition in which heart function is insufficient to supply the organs with enough blood nutrients. The consequence is a progressive cascade of changes that lead to fatigue, shortness of breath and, ultimately, death. Much progress has been made in understanding the molecular and cellular processes that contribute to HF. Despite these insights and modern treatment options, chronic HF remains a major cause of illness and death and generally has a poor prognosis. Because HF is more common with increasing age, the number of affected individuals is rising rapidly with the ageing population. Thus, new treatments directed at critical disease mechanisms are needed to halt and reverse the devastating consequences of this disease.
Here, we focus on chronic HF and our understanding of molecular disease mechanisms related to Ca 2? metabolism. Many insights into HF stem from the elucidation of intracellular signaling pathways that mediate cardiac performance as well as contribute to cardiac dysregulation under disease conditions. The clinically critical transition occurs when the heart can no longer provide adequate blood flow and/or pressure to meet the body's demands. Consequently, physiological countermeasures include the stimulation of neurohormonal outflow and the activation of intracellular signaling cascades. These acute responses may initially offset reduced cardiac performance. However, sustained stimulation of the heart by cellular stress signaling cascades ultimately increases the likelihood of organ failure and contributes to a worse prognosis.
Cardiac remodeling and changes in intracellular signaling
HF is characterized by chronic activation of neuro-hormonal pathways representing a compensatory response to overcome depressed cardiac function. However, over weeks to months, a chronic hyperadrenergic state ensues with elevated plasma catecholamine levels, which contribute to maladaptive cardiac chamber remodeling, progressive deterioration of pump function, and deadly arrhythmias. Due to the chronic hyperadrenergic state, desensitization of b-adrenoreceptors (b-ARs) and reduced global intracellular cAMP synthesis occur in the failing heart [1] [2] [3] . However, stimulation of b-ARs and other signaling pathways is maintained and continues to affect the remodeled cells and proteins.
A broad range of molecular pathways are involved in the development of HF, and there is likely to be substantial overlap between these pathways. Typically, cell-surface receptors are activated by ligands leading to the activation of stress-response protein kinases and phosphatases such as cAMP-dependent protein kinase A (PKA), protein kinase C (PKC), protein kinase D (PKD), mitogen activated kinases (MAPKs), Ca 2? calmodulin-dependent kinase II (CaMKII), and calcineurin. Chronic activation of these stress pathways and their cellular effectors including transcription factors, which target multiple genes, result in changes in cellular structure, function, and overall regulation of the heart, collectively referred to as cardiac remodeling. Additionally, an imbalance between cell survival and cell death pathways results in a low rate of cardiomyocyte apoptosis which may contribute to cell loss in HF [4, 5] exchanger (NCX) (Fig. 1a) . transport proteins themselves (Table 1) , become significantly altered during remodeling of the failing heart [8] . [12] . Moreover, recombinant aequorin can be targeted to specific subcellular compartments through signal sequences [13] . However, recombinant aequorin emits a relatively small signal upon Ca 2? binding which compromises the measurement of Ca 2? concentrations in smaller cells at the cost of low time resolution [14] . Tsien and colleagues synthesized the first, rationally designed, fluorescent Ca 2? indicator for intracellular use based on the Ca 2? -chelator EGTA [15] . The widespread and successful use of fluorescent polycarboxylate dyes started with the introduction of lipophilic acetoxymethyl (AM) ester derivatives allowing efficient and stable indicator loading of living cells without potentially damaging pipette injection techniques [16] .
Milestones toward imaging of intracellular calcium metabolism

Global intracellular calcium abnormalities in heart failure
Pioneering studies used injection of the aequorin Ca 2? sensor into physiologically contracting muscle preparations from explanted human hearts. Aequorin loaded muscles from failing hearts showed a reduced capacity to restore nanomolar resting Ca 2? levels during diastole in conjunction with depressed muscle contraction and relaxation [17] . Different from healthy heart muscle and pronounced at faster rates, the aequorin injected failing heart muscle showed a reduced amplitude of the intracellular Ca ] i ) together with diminished force production [18] . Additionally, myothermal measurements in isolated muscle strip preparations from failing and nonfailing human hearts showed that the thermal equivalent of total Ca 2? cycling is reduced significantly in HF [19] . The rate of heat production was significantly reduced indicating reduced SR Ca 2? uptake [19] . Consistent with multicellular muscle preparations, dissociated single cardiomyocytes from failing human hearts displayed a prolonged relaxation, depressed systolic contraction, and elevated diastolic tension [20] [23, 26] , hypertension induced hypertrophy HF in salt-sensitive rats [24] , rats with (Fig. 1a) ] i /I Ca ) which has been confirmed in rats with myocardial infarction [27] , dogs with pacing-induced HF [34] , mice with viral myocarditis [29] , and muscle LIM protein knockout mice [35] . Additionally, structural changes of the T-tubules, SR storage organelles, and/or the architecture of the junctional microdomain cleft are all likely contributors to defective EC coupling by altering the geometry of the Ca 2? release unit potentially resulting in orphaned RyR2 release channels and/or abnormal CICR [36, 37] .
Abnormal calcium release triggers fatal arrhythmias
Sudden unexpected death accounts for up to 50% of all deaths in HF patients and is most often due to ventricular tachyarrhythmias [38] . Both reentry and focal mechanisms have been documented in patients with ischemic cardiomyopathy [39] [47, 48] . Consistent with a b-AR and cAMP mediated stress mechanism, PKA phosphorylated RyR2 channels containing CPVT mutations showed a significant gain-of-function defect and a Ca 2? leak mediated arrhythmia trigger mechanism [49, 50] . Indeed, cardiomyocytes from knockin mice with the RyR2-R2474S mutation identified earlier in CPVT patients [47] showed Ca 2? leak mediated I TI currents and DADs during stimulation with catecholamines (Fig. 1b) dependent arrhythmia initiation which can be targeted and tested by a novel class of RyR2 stabilizing compounds [51] ( Table 2) . exchanger (NCX) [54] . The ratio of PLN:SERCA2 is a critical determinant of cardiac Ca 2? homeostasis, and increases in this ratio have been suggested to contribute to increased diastolic Ca 2? levels and cardiac dysfunction [53, 55, 56] . On the other hand, due to the changes in the relative expression and function of NCX and SERCA2, a net shift toward increased Ca 2? extrusion to the extracellular space and a net decrease in SR Ca 2? uptake occurs (Fig. 1c) [31] likely due to chronically increased RyR2 phosphorylation [57] and consistent with an increased propensity for Ca 2? induced arrhythmias in HF.
Storage organelle and calcium transport dysfunction
Molecular mechanisms of depressed SR calcium uptake
Decreased SERCA2 function has been associated with changes in the regulatory subunit PLN (Fig. 1c) . PLN is a phosphoprotein which inhibits SERCA2 in its dephosphorylated state, while phosphorylation of PLN during b-AR stimulation relieves this inhibitory effect. The regulatory role of PLN in myocardial contractility has been established through the generation and characterization of genetically altered mouse models, which revealed a correlation between PLN expression and contractile function [58] [59] [60] . PLN phosphorylation in HF is chronically decreased (PLN hypophosphorylation) which may directly contribute to depressed SR Ca 2? uptake [61] . Chronic PLN hypophosphorylation can be predicted to compromise cardiac stress adaptation mediated by cAMP and PKA. Overexpression of the cardiac SERCA2a isoform or the constitutively PKA phosphorylated PLN-Ser 16 improved function in rats following aortic banding-induced HF [62] and decreased arrhythmia susceptibility following ischemia-reperfusion cardiomyopathy in pigs [63] .
Phospholamban is potently inhibited by phosphatase 1 (PP1), which in turn is inhibited by phosphatase inhibitor I-1 following PKA phosphorylation and I-1 activation. Consistent with this mechanism, overexpression of an activated I-1 form in mice protects the animals from HF development [64] . Moreover, the identification of PLN mutations in patients with dilated cardiomyopathy has strengthened its critical role in cardiac function. Thus, inhibition of PLN activity and restoration of SR Ca 2? cycling were suggested to hold promise for treating heart failure [65] .
Molecular mechanisms of intracellular calcium leak
In samples from patients and animals with HF, RyR2 is chronically PKA hyperphosphorylated contributing to intracellular Ca 2? leak and remodeling of the macromolecular channel complex [7, 66, 67] . If the hyperadrenergic state in HF leads to secondary downregulation of b-adrenergic signaling and globally reduced intracellular cAMP synthesis, which molecular mechanism maintains RyR2 PKA hyperphosphorylation and intracellular Ca 2? leak? During HF, phosphatases (PP1 and PP2A) are depleted from the RyR2 complex which may contribute to a reduced rate of RyR2 dephosphorylation [61, 66] . In human HF, the cAMP-specific phosphodiesterase isoform PDE4D3 was found to be decreased in the RyR2 complex paralleled by a decrease in cAMP hydrolyzing activity [57] . Thus, PKA hyperphosphorylation and calstabin2 depletion may both (Fig. 1c) . Indeed, single RyR2 channels from human failing hearts showed an increased open probability consistent with intracellular Ca 2? leak [66] . Using site-directed mutagenesis of RyR2, a specific Ca 2? /calmodulin-dependent protein kinase II (CaMKII) phosphorylation site (Ser 2814 ) distinct from the PKA phosphorylation site (Ser 2808 ) has been identified [6] . CaMKII phosphorylation increased RyR2 Ca 2? sensitivity and open probability. Since CaMKII was activated by higher cardiac pacing rates, RyR2 CaMKII phosphorylation may contribute to enhanced CICR and enhanced contractility at higher heart rates. However, the ratedependent increase in RyR2 phosphorylation by CaMKII as seen in sham-operated, healthy rat hearts was compromised in rat hearts with HF [6] . Transgenic mice overexpressing the cytosolic CaMKIId c isoform develop cardiac hypertrophy, HF, and intracellular Ca 2? leak [68] . Acute overexpression of CaMKIId c in cardiomyocytes resulted in significant SR Ca 2? leak without changes in contractile function [69] . Adenoviral CaMKII overexpression was not associated with calstabin2 dissociation from RyR2 [69] confirming earlier results [6] . On the other hand, PKA phosphorylation of RyR2 resulted in depletion of the stabilizing calstabin2 subunit [6] , and decreased calstabin2 levels have been linked to Ca 2? triggered arrhythmias in the structurally normal heart [49] . Disruption of RyR2 PKA phosphorylation in Ser2808Ala knockin mice with myocardial infarct induced HF has provided evidence that PKA hyperphosphorylation induced SR Ca 2? leak may directly contribute to HF progression [70] . However, the significance of concomitant PKA and/or CaMKII RyR2 phosphorylation in Ca 2? dysregulation during HF has not been addressed conclusively.
Altered sodium handling in heart failure
Intracellular Na
? and Ca 2? concentrations are intricately coupled through the NCX current. In addition, Na ? influx through sarcolemmal Na V 1.5 channels contributes to intracellular [Na ? ] i homeostasis (Fig. 1a) . Studies about [Na ? ] i in human myocardium showed a stimulation rate dependent increase in [Na ? ] i [71, 72] . For any given stimulation rate, human end-stage failing myocardium showed a shift toward higher intracellular [Na ? ] i [71] . In a rabbit HF model with elevated [Na ? ] i , the function of the Na ? /K ? -ATPase function was found normal [73] . A potential role of altered Na
? channel inactivation and a significantly increased late I Na,L in HF as a cause of intracellular [Na ? ] i overload has been documented in animal models of HF and human failing myocardium [74, 75] overload and contractile dysfunction. Interestingly, pharmacological inhibition of I Na,L was found to improve diastolic dysfunction in failing human myocardium [76] . Additionally, increased late I Na,L may result in Ca 2? induced electrical cardiomyocyte dysfunction as shown in SCN5A-DKPQ knockin mice resembling the Long-QT3 syndrome [77] .
Altered force frequency relation in the failing human heart
Pathophysiological consequences of altered EC coupling have an immediate impact on cardiac stress adaptation during higher heart rates. The force-frequency relation (FFR) or staircase phenomenon of healthy human myocardium and within physiological limits describes a heart rate dependent increase in contractile force and cardiac output. However, in failing human hearts or isolated muscle preparations, the frequency-dependent potentiation of contractile force is blunted or, even worse, inversed [78] . Alteration of the FFR in the failing human heart has been accepted as a functional milestone which may partially explain the decreased exercise capacity of symptomatic HF patients. [18] . Alterations of the frequency response of contractile performance have been confirmed in vivo in HF patients [79] . A different experimental protocol which is thought to enable increased Ca 2? accumulation into the SR stores in diastole, uses post-rest pacing which typically produces an increase in developed force in healthy myocardium also referred to as 'post-rest potentiation'. However, alterations in post-rest potentiation that may underlie reduced stress adaptation and the FFR inversion have been associated with a blunted post-rest D[Ca 2? ] i increase of SR Ca 2? content (Fig. 2 ) [80] . While in healthy human myocardium a pronounced upregulation of SR Ca 2? content occurs at higher heart rates, failing human myocardium shows a blunted regulation of SR Ca 2? content [26] . Therefore, the chronic hyperadrenergic state and associated higher heart rates in HF patients may create an increased risk for Ca 2? induced cardiac dysfunction and arrhythmias. Accordingly, novel therapeutic strategies have successfully used pharmacological heart rate reduction in HF patients to improve prognostic outcome [81] .
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Therapeutic rationales to modulate calcium handling in heart failure Several therapeutic rationales exist which aim to correct known molecular Ca 2? signaling abnormalities in HF as summarized in Table 2 . Among these strategies, NCX blockers may have therapeutic utility if mode-selective block can be established and/or risks for disturbing intracellular Ca 2? metabolism can be avoided. Partial inhibition of NCX by SEA-0400 in MLP -/-knockout cardiomyocytes with heart failure showed a net gain of [Ca 2? ] i and SR load but no improvement in contractility whereas cardiomyocytes from mice with aortic-banding induced hypertrophy and HF showed improved contractile function [82] . Further development of NCX blockers for HF will depend on the critical assessment of the potential benefits of NCX reduction versus effects on [Ca 2? ] i by refining mode dependence and/or including additional targeting strategies.
Some traditional ion channel blockers like tetracaine inhibit ion permeation through RyR2 channels, however, lack of specificity and potential side effects on contractile function indicate significant limitations toward therapeutic applicability [83, 84] . Recently, the efficacy of novel RyR2 channel stabilizing drugs of the 1,4-benzothiazepine class (JTV519 or K201) which stabilize the RyR2 closed state but do not block ion permeation has been established in animal models of heart failure where they inhibit progression of cardiac remodeling and dysfunction [57, 85, 86] . RyR2 stabilizing compounds with high specificity and cardiac activity have been developed [51] and their efficacy as potential HF treatment is under investigation. Additionally, b-blockers and angiotensin-II receptor blockers have been associated with beneficial effects on RyR2 channel dysfunction in HF through mechanisms which indirectly prevent excess post-translational modification of RyR2, e.g. by PKA hyperphosphorylation or nitrosylation [87] [88] [89] .
Adeno-associated viruses (AAVs) are currently best suited for myocardial gene delivery due to minimal pathogenicity and several serotypes exhibit tropism for the heart. Following identification and comprehensive characterization of SERCA2a as a potential therapeutic target in HF, cardiac gene therapy trials using replication-deficient viral vectors (AAV-SERCA2a) have been approved by the US Food and Drug Administration and are under review with the UK regulatory authorities for clinical trials [90] . Summary and future perspectives HF is characterized by chronic maladaptive changes and a poor prognosis. Chronic activation of intracellular signaling pathways mediates structural and functional remodeling of the failing heart. Changes in EC coupling at the level of local and global Ca 2? signals represent a key mechanism of contractile depression and arrhythmia propensity. It has become increasingly clear that cardiac remodeling in HF occurs within cytosolic Ca 2? signaling microdomains. Translational approaches about the local and global Ca 2? signaling mechanisms, remodeling mechanisms, and related disease processes will be of key importance to develop novel and specific therapeutic rationales. We anticipate that Ca 2? imaging techniques will significantly increase our understanding of the cardiac pathophysiology underlying HF and boost development of novel therapeutic strategies in the future.
